Interim Report January – March 2009 Tripep AB (publ)

• Research and development costs amounted to SEK 1.1 (6.6) m
• The loss after tax was SEK -3.5 (-9.9) m
• Earnings per share were SEK -0.15 (-1.66)
• The company had no net sales for the period
• In a mutual understanding with the Tripep Board CEO Jan Nilsson left the Company on March 31st. Head of Research Anders Vahlne took office as new CEO on April 1st
• The last three patients have started their high-dose treatment in the ChronVac-C® study
• Data from the ChronVac-C® study were presented at the International Symposium on Viral Hepatitis and Liver Diseases in Washington held between March 20 and 24 2009
• On January 23rd the Swedish Medical Products Agency approved the start of the phase I/II study with ChronSeal®, a study now ongoing in Norway and Sweden
• Through Tripep’s partner Kringle Pharma an option agreement has been signed with the Japanese specialty pharma company Maruho regarding ChronSeal®


For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se



About Tripep
Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website:
www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.